FDA中国办公室位于北京朝阳区安家楼路55号美国大使馆里。
电话:+86-10-8531-3924
传真:+86-10-6532-2032
邮箱:USFDAChinaOffice@state.gov
以下为在该办公室工作的FDA检查员的名单和他们检查过的企业以及发现的缺陷信息(发现这些缺陷并不代表这些企业GMP检查不合格),读者可以从中获取这些检查官的检查习惯。
Peter E. Baker
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
海南双成药业有限公司
Sufficient controls are not established over laboratory instrumentation.
实验室仪器未建立足够的控制
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
浙江九洲药业有限公司
Maintenance activities are not recorded in equipment use logs as required by your SOP SMP-CH-01, "Hygiene Management".
设备使用日志未按照SOP要求记录维修活动。
Ipca Laboratories Ltd.
IPCA实验室
Laboratory control records do not include complete data derived from all tests conducted to ensure compliance with established specifications and standards.
QC记录没有包括所有用以确保符合既定规范和标准的检验的完整数据。
Chifeng Pharmaceutical Co., Ltd.
赤峰制药有限公司
Laboratory control procedures are not followed.
未遵循实验室控制规程
Chongqing Pharmaceutical Research Institute Co., Ltd.
重庆医工院
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
BrightGene Bio-Medical Technology
博瑞生物医药技术
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
Shanghai Desano Chemical Pharmaceutical Co., Ltd.
上海迪赛诺化学制药有限公司
Written production control procedures are not followed.
未遵循实验室控制规程。
Zhejiang Hisoar Pharmaceutical Co., Ltd.
浙江海翔药业有限公司
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
石药集团中诺药业(石家庄)有限公司
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
Zhejiang Hisun Pharma Co., Ltd.
浙江海正药业有限公司
Quality Control laboratory procedures are not followed.
未遵循实验室控制规程。
典型案例
Our investigators reviewed audit trails from various stand-alone pieces of laboratory equipment you used to perform high performance liquid chromatography (HPLC) and gas chromatography (GC) analyses. Our investigators found that you had deleted entire chromatographic sequences and individual injections from your stand-alone computers.
我们的检查员(Peter Baker)审核了多台用于高效液相色谱分析和气相色谱分析的单机版实验室设备的审计追踪。我们的检查员发现你们在该单机版电脑上删除了全部色谱序列和个别进样。
For example, your written system suitability procedure for (b)(4) requires only six injections. However, your records showed that on January 5, 2016, you injected seven system suitability standards when performing system suitability for batch #(b)(4). The audit trail showed that the final standard injection was permanently deleted from the instrument’s computer. Your analyst told our investigator that it is laboratory practice to perform more injections than are required by the procedure, and then delete any undesirable result to ensure passing system suitability results.
例如,你们的系统适应性的书面规程只要求进6针。但是你们的记录显示在2016年5日,你们在进行XX批次系统适应性时,进了7针标准品。审计追踪显示最后一针标准品被从该仪器的电脑上删除了。你们的分析员告诉检查官比要求的多进几针然后删除不好的结果以确保通过系统适应性是实验室规范的做法。
Lindsey M. Schwierjohann
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
海南双成药业有限公司
Sufficient controls are not established over laboratory instrumentation.
实验室仪器未建立足够的控制
Shandong Lukang Pharmaceutical Co., Ltd.
山东鲁抗制药有限公司
Controls to prevent cross contamination in the API warehouse are not in place.
API库房缺乏防止交叉污染的控制措施
Yantai Dongcheng Pharmaceutical, Co, Ltd.
烟台东诚药业有限公司
Failure to document all analytical test results in the laboratory records and the equipment user logbook and failure to conduct an investigation into out-of-specification results.
实验室记录和设备使用日志未能记录所有分析结果,以及未能调查OOS结果。
Christopher T. Middendorf
Tianjin Jingye Fine Chemicals Co., Ltd.
天津市敬业精细化工有限公司
QC analysts re-inject HPLC samples without justification, written documentation or approval.
QC分析员重复进样而没有论证、书面文件记录和批准。
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
浙江九洲医药有限公司
Maintenance activities are not recorded in equipment use logs as required by your SOP SMP-CH-01, "Hygiene Management".
设备使用日志未按照SOP要求记录维修活动。
典型案例
浙江九洲:
检查官在查看某设备的使用、清洁和维保日志时,发现检查之前那天的记录没有写。你们操作人员说那行留为空白是为了给上一班次补上他们做的清洁操作。在检查期间,我们检查官发现你们的生产记录中也有类似的数据缺失或数据填写滞后的现象。这种操作不符合CGMP要求。操作人员被告知公司没有体系用来报告这种记录中的滞后情况,这种记录失误是不需要进行偏差调查的,也不需要通知质量部门。
在检查期间,你们质量部门的一名员工还给检查官出示了一份批记录,其中有他的签名,他说他已经对该批记录进行了审核。该员工后来承认,他伪造了该CGMP记录,并说事实上他并没有进行审核,完全不顾其实他已经在该批记录上作为QA审核员签字并已放行了该批产品。上述这种数据做假和记录保存缺陷使得我们非常怀疑你们公司记录的有效性。
我们的检查官在这次检查中注意到纯化水系统有一个地方有泄漏,值得注意的是前一次检查中也是这套纯化水系统被发现有类似的问题。你们对上次检查的回复中所描述的预防措施其实并未足以让你们的员工发现和修补纯化水系统的泄漏,因此,我们很质疑现有的措施是否有效。在对本警告信的回复中,请说明为什么原来的措施没起作用,已采取了什么新的措施,为什么新的措施会起作用。
这次检查中还发现其它生产设备也处于需要修理的状态,因此在将来的检查中,我们会更详细地审核你们修订过的预防性维保计划。
在对本警告信的回复中,要提交一份综合的整改行动计划,说明你公司保证数据完整性的方式。我们强烈推荐你们聘请一位对数据完整性问题具有较好经验的第三方审计员,让他帮助你们评估你们的整体GMP符合性。
在本次检查中,你们质量部门的员工说该部门的工作量对于现在的人员数量来说太大了。我们发现的这些重大问题显示你们质量部门无法完全履行其职责。例如,在检查期间,你们的运营主管告诉我们检查官说你们的质量部门还没有时间对那个月生产的所有产品进行审核。你有责任保证给质量部门提供充分适当的资源,使他们能完成自己的工作。
Marijo B Kambere
Chongqing Pharmaceutical Research Institute Co., Ltd.
重庆医工院
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
Guang Gao
BrightGene Bio-Medical Technology
博瑞生物医药技术
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
Zhejiang Hisoar Pharmaceutical Co., Ltd.
浙江海翔药业有限公司
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
典型案例
1. Failure to maintain complete data derived from all laboratory tests conducted to ensure compliance with established specifications and standards.
未能维护化验室内进行测试期间产生的完整数据,无法确保其符合既定质量标准。
During the inspection, FDA investigators discovered a lack of basic laboratory controls to prevent changes to your electronically-stored data and paper records. When you encountered suspect and out-of-specification (OOS) results, you retested samples until you obtained desirable results. You did not investigate, review, or report original results. You relied on incomplete records to evaluate the quality of your drugs and to determine whether your drugs conformed to established specifications and standards.
在检查期间,FDA检查人员发现贵公司缺乏基本的实验室控制,无法防止对你们的电子存贮数据和纸质记录进行更改。当你们碰到可疑和OOS结果时,你们对样品进行复验直到获得想要的结果。你们并未调查、审核或报告原始结果。你们依赖于不完整的记录来评估你们药品的质量,决定你们的药品是否符合既定的质量标准。
For example, during the inspection, we reviewed electronic data from your high performance liquid chromatography (HPLC) system. An unknown impurity peak was present when the original three-month stability sample of (b)(4) batch (b)(4) was run on October 9, 2014. This unknown peak was OOS and would have caused the sample to fail for unknown impurities, but it was not included in the official record for this stability test. Instead, an analyst ran a new sample to obtain a passing result on October 10, 2014, and only the passing result from the second sample was reported in the official record.
例如,在检查期间,我们审核了你们HPLC系统中的电子数据。在2014年10月9日某批次的3个月稳定性试验的原始样品检测中出现了一个未知杂质峰。此未知杂质峰是OOS,应该判定样品未知杂质不符合标准,但这个结果没有放进此稳定性的正式检测记录中。一个化验员在2014年10月10日进行了新样品的检测,并获得了符合标准的结果,在正式记录里只报告了第二个样品的符合标准的结果。
In your response, you stated that the analyst thought that the unreported OOS value was related to the reference solution and not the sample being tested. You said the analyst was afraid of making mistakes, and invalidated the data without notifying management. You acknowledged that the data should not have been invalidated without an OOS investigation and committed to revise procedures.
在你们的回复中,你们声称化验员以为未报告的OOS值是对照液的,而不是供试样品的。你们说化验员害怕犯错,因此没有通知管理人员就将该数据删除了。你们知道该数据不应该不经过OOS调查就宣布无效,并且承诺要修订程序。
2. Failure to prevent unauthorized access or changes to data, and to provide adequate controls to prevent manipulation and omission of data.
未能防止未经授权即进入或改变数据,未能提供足够的控制来防止对数据的篡改和省略。
During the inspection, we observed that your laboratory systems lacked access controls to prevent deletions or alterations to raw data. For example, our investigator reviewed the electronic folder containing data files generated when your firm tested (b)(4) batches of (b)(4) API for residual solvents by gas chromatography (GC). The investigator compared the file names in the folder with the metadata generated by the Chemstation software you used to operate your GC system, and found that two chromatograms had been deleted from the system. Because there were no controls restricting operators’ or supervisors’ abilities to alter or manipulate the data, an analyst had completed two runs and deleted the results, and then changed the subsequent file names in the folder where reported data was stored to make it appear that the deleted runs never occurred.
在检查期间,我们发现你们的化验室系统缺乏登录控制,无法防止对原始数据的删除或修改。例如,我们检查员审核了包括有数据文件的电子文件夹,其中是你们GC检测某批原料药残留溶剂的。检查员将文件夹里的文件名称与你们用来运行GC系统的CHEMSTATION工作站产生的元数据进行了比较,发现系统里有2份色谱图被删除了。由于没有控制来限制操作人员或主管修改或伪造数据的权限,一个化验员做了2针测试,然后删除了结果,之后修改了存贮所报告的数据的文件夹中的文件名,让它看起来像是没有删除过样品测试一样。
In your response, you stated that two injections were deleted from the system because the analyst believed that an unstable baseline made retaining the files unnecessary. You also confirmed that your software had no access controls and that your analysts had authorization to delete data.
在你们的回复中,你们声称从系统里删除这2针是因为化验员相信没有必要将基线不稳定的色谱数据保留下来。你们还承认你们的软件没有权限控制导致你们的化验员可以删除数据。
3. Failure to record activities at the time they are performed.
未能在活动实施的同时进行记录。
During the inspection, we observed that you did not have worksheets for recording microbial test results and that you failed to contemporaneously document microbial limits test results for (b)(4) API batch (b)(4).
在检查期间,我们发现你们没有记录纸来记录微生物检测结果,你们没有同步记录某批原料药的微生物限度测试结果。
Chiang Syin
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
石药集团中诺药业(石家庄)有限公司
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
Qilu Tianhe Pharmaceutical Co., Ltd.
齐鲁天河药业有限公司
Batch manufacturing instructions are not followed.
未遵循批生产指令。
Gang Wang
Yantai Dongcheng Pharmaceutical, Co, Ltd.
烟台东诚制药有限公司
Failure to document all analytical test results in the laboratory records and the equipment user logbook and failure to conduct an investigation into out-of-specification results.
实验室记录和设备使用日志未能记录所有分析结果,以及未能调查OOS结果。
Zhejiang Hisun Pharma Co., Ltd.
浙江海正药业有限公司
Quality Control laboratory procedures are not followed.
未遵循实验室控制规程。
Changzhou Qianhong Bio-pharma Co., Ltd.
常州千红生化制药有限公司
Failure of your Quality Unit to ensure that materials are appropriately tested and results are reported.
质量部门未能确保物料得到适当的检验并报告结果。
Thomas J. Cosgrove
BrightGene Bio-Medical Technology
博瑞生物医药技术
Laboratory Control procedures are not followed.
未遵循实验室控制规程。
Pharmacia & Upjohn Co., LLC
法玛西亚普强有限公司
Documented investigations into discrepancies and out-of-specification results are not fully investigated.
不合格和OOS结果的调查不充分。
Marie F. Morin
Changzhou Qianhong Bio-pharma Co., Ltd.
常州千红生物制药有限公司
Failure of your Quality Unit to ensure that materials are appropriately tested and results are reported.
质量部门未能确保物料得到适当的检验并报告结果。
SkyePharma Production SAS
Deviations from written production and process control procedures were not recorded.
未报告书面生产和工艺控制规程的偏差。
公众号
GMP办公室
专业的GMP合规性研究组织
国内外(FDA、EMA、MHRA、CFDA、WHO、PIC/S等)GMP法规解读;
国内外制药行业GMP监管动态;
GMP技术指南(ISPE、PDA、ISO、ASTM等)分享